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Background: Altered expression of microRNAs (miRNAs) commonly accompanies colorectal (CRC) and endometrial
carcinoma (EC) development, but the underlying mechanisms and clinicopathological correlations remain to be
clarified. We focused on epigenetic mechanisms and aimed to explore if DNA methylation patterns in tumors
depend on DNA mismatch repair (MMR) status, sporadic vs. Lynch-associated disease, and geographic origin
(Finland vs. Australia). Treatment of cancer cell lines with demethylating agents revealed 109 significantly
upregulated miRNAs. Seven met our stringent criteria for possible methylation-sensitive miRNAs and were
used to screen patient specimens (205 CRCs and 36 ECs) by methylation-specific multiplex ligation-dependent
probe amplification.
Results: Three miRNAs (129-2, 345, and 132) with low methylation levels in normal tissue and frequent
hypermethylation in tumors were of particular interest. Hypermethylation of miR-345 and miR-132 associated
with MMR deficiency in CRC regardless of geographic origin, and hypermethylation of miR-132 distinguished
sporadic MMR-deficient CRC from Lynch-CRC. Finally, hypermethylation of miRNAs stratified 49 endometrial
hyperplasias into low-methylator (simple hyperplasia) and high-methylator groups (complex hyperplasia with
or without atypia) and suggested that miR-129-2 methylation in particular could serve as a marker of progression
in early endometrial tumorigenesis.
Conclusions: Our study identifies miR-345 and miR-132 as novel differentially methylated miRNAs in CRC, thereby
facilitating sub-classification of CRC and links miR-129-2 methylation to early endometrial tumorigenesis.
Keywords: miRNA, Methylation, Microsatellite instability, Lynch syndrome, Colorectal cancer, Endometrial cancerBackground
MicroRNAs (miRNAs) are small non-coding RNAs that
control gene expression by binding to complementary
sequences in the 3′UTR of target mRNAs, thereby indu-
cing mRNA degradation or translational repression [1].
More than 1,400 human miRNAs are known [2], and
these may regulate about one third of all human genes [3].
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unless otherwise stated.and transcribed independently, whereas another half are
intragenic (located within introns of host genes) and can
be, but not necessarily are, co-transcribed with their host
genes [4].
Downregulation of tumor suppressive miRNAs (target
proto-oncogenes) and upregulation of oncogenic miRNAs
(target tumor suppressor genes) is a feature of cancer [5].
Over half of miRNA promoters contain a CpG island as a
possible target for aberrant methylation 6[6] which can
lead to miRNA dysregulation. The CpG island is typic-
ally located in the proximal upstream region (<2 kb
of pre-miRNAs) for intergenic miRNAs and independentlyis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Kaur et al. Clinical Epigenetics  (2015) 7:20 Page 2 of 13regulated intronic miRNAs, but can reside far upstream
(>20 kb of pre-miRNAs) for intronic miRNAs utilizing the
host transcription start sites [6-8]. Epigenetically silenced
miRNAs can be reactivated in cancer cell lines by treat-
ment with the DNA methyltransferase inhibitor 5-aza-2′-
deoxycytidine (5-aza-CdR), often combined with a histone
deacetylase inhibitor (such as trichostatin A, TSA), and
analogous drugs can be used for epigenetic cancer therapy
in patients [9].
Colorectal cancer (CRC) can develop via two main
routes, the microsatellite instability (MSI) pathway (ap-
proximately 15% of CRCs), or the chromosomal instabil-
ity (CIN) pathway (approximately 85% of CRCs) [10].
The most frequent cause of MSI is somatic methylation
of the DNA mismatch repair (MMR) gene MLH1 and
involves the CpG island methylator phenotype (CIMP).
Lynch syndrome (LS), which is associated with germline
mutations in one of four MMR genes, MLH1, MSH2,
MSH6, and PMS2, underlies one fifth of MSI cancers
[10]. In LS, tumor suppressor methylator phenotypes
vary between cancers arising in different organs, and theFigure 1 Flow chart of this investigation.patterns are partly different compared to the correspond-
ing sporadic cancers [11,12].
This study took advantage of principles described
above to search for novel epigenetically silenced tumor-
suppressive miRNAs that might play a role in colorectal
and endometrial tumorigenesis and discriminate tumors
according to their molecular characteristics (MMR sta-
tus and sporadic vs. Lynch-associated disease), geographic
origin (Finland vs. Australia), and developmental stage
(benign vs. malignant histology). Results of seven miRNAs,
including three of particular interest (miR-129-2, miR-345,
and miR-132) will be reported.
Results
Study design
To identify methylation-sensitive miRNAs associated
with colorectal and endometrial tumorigenesis, cancer cell
lines and clinical specimens were utilized according to a
scheme depicted in Figure 1. The cell lines (Additional
file 1: Table S1) were selected to represent the main mo-
lecular subtypes of the patient series (Table 1) with the
Table 1 Basic molecular and clinicopathological characteristics of the study series
Finnish CRC Australian CRC Finnish EC
Sporadic
MSS
Sporadic
MSI
Lynch Sporadic
MSS
Sporadic
MSI
Lynch
Total number of tumors 47 40 28 52 38 36
Gender
Female 27 27 12 25 20 36
Male 20 13 16 27 18 -
Mean age of diagnosis (years) 69.9 72.8 43.6 67.6 67.1 50.2
Germline mutation present in MMR genes (total) N/A N/A 28 N/A N/A 36
MLH1 28 30
MSH2 0 3
MSH6 0 3
MMR statusa
Deficient 0 40 28 0 38 36
Proficient 47 0 0 52 0 0
Tumor grade
1 13/21 5/14 5/16 1/52 0/36 14/29
2 5/21 6/14 6/16 46/52 24/36 9/29
3 3/21 3/14 5/16 5/52 12/36 6/29
Tumor stage (Dukes/WHO/FIGO)b
A/I/I 7/46 2/37 5/19 8/52 3/38 12/22
B/II/II 16/46 24/37 10/19 24/52 20/38 7/22
C/III/III 16/46 8/37 4/19 17/52 13/38 1/22
D/IV/IV 7/46 3/37 0/19 3/52 2/38 3/22
Location of CRCc
Proximal 20/44 34/39 22/27 20/52 27/38 -
Distal 24/44 5/39 5/27 32/52 11/38 -
N/A, not applicable. aBased on microsatellite instability and immunohistochemical staining; baccording to the Dukes (A-D), World Health Organization (WHO) (I-IV),
and International Federation of Gynecology and Obstetrics (FIGO) (I-IV) staging for CRC and EC, respectively. The denominator indicates the number of tumors for
which data were available. cPrior to the splenic flexure for ‘proximal’ and distal to the splenic flexure for ‘distal’ (the denominator indicates the number of tumors
with data available).
Kaur et al. Clinical Epigenetics  (2015) 7:20 Page 3 of 13MMR-proficient SW480 and T84 corresponding to spor-
adic microsatellite stable (MSS) colorectal cancers, RKO
and AN3CA (MMR-deficient due to presumably biallelic
MLH1 promoter methylation) equivalent to sporadic MSI
cancers and HCT15, HCT116, and HEC59 (MMR-deficient
as a result of MMR gene mutations) analogous to LS-
CRC and LS-EC. While cell lines tend to have stronger
methylator phenotypes than primary tumors, the basic
patterns of CIMP are often broadly comparable in cell
lines and primary tumors, including tissue-specific in-
volvement of marker loci and relationship to genomic in-
stability [11,13-15]. Criteria to select miRNAs from cell
line experiments for the subsequent screen of clinical
samples (Figure 1) were based on bioinformatic and litera-
ture analyses on the one hand (associated with CpG is-
land; predicted to target genes relevant in colorectal and
endometrial tumorigenesis; expressed in the intestine and
endometrium; intergenic; HhaI site present in CpG island)and our own experimental data on the other hand (low
expression in cancer cell lines compared to respective
normal tissues; methylated in the cell lines before treat-
ment and showing significant upregulation along with re-
duced methylation of various degrees after treatment).
Altogether, 109 miRNAs were upregulated at least twofold
in one or more cell lines (Additional file 2: Figure S1).
Among those, 46 were associated with CpG islands.
Among these, seven miRNAs with a high a priori probabil-
ity of representing novel methylation-sensitive, intergenic/
independently regulated tumor-suppressive miRNAs ac-
cording to the abovementioned criteria were chosen for
the analysis of patient specimens.
Aberrant methylation of miRNA-associated CpG islands in
CRC and EC
The seven miRNAs of interest were investigated for CpG
island methylation (Additional file 3: Figure S2, Additional
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imens (205 CRC and 36 EC, Table 1) to explore if methy-
lation in tumor DNA differs from that in paired normal
DNA and if patterns specific to individual patient groups
might be detectable. We opted for a methylation-specific
multiplex ligation-dependent probe amplification (MS-
MLPA)-based approach, which allows for multiplex, quan-
titative analysis of methylation in archival formalin-fixed,
paraffin-embedded (FFPE) specimens without the need of
bisulfite conversion [16]. A representative electrophero-
gram from MS-MLPA analysis is shown in Figure 2. MS-
MLPA data from normal and tumor DNAs from all 241
cases, divided into six patient groups, are shown in Figure 3
(box plots of distributions of individual Dm values) and
Additional file 6: Table S4 (averages and standard devia-
tions of Dm values). Three different methylation patterns
emerged. First, miR-129-2, 345, and 132 showed low levels
of methylation in normal DNA (with average Dm values
around 0.20 or below) and increased methylation in tumor
DNA; the difference was statistically significant in most
patient groups. Second, miR-572, 663, and 34a had con-
siderable methylation in normal DNA already (with aver-
age Dm values clearly exceeding 0.20), and methylation
increased in tumor DNA. Third, miR-375 showed little
methylation (for both probe I and probe II) and no differ-
ence between normal and tumor DNA. The pattern dis-
played by the first set of miRNAs was considered to haveFigure 2 Electropherograms for paired normal and tumor DNA to illu
A single case from the Finnish MSI-CRC group is shown. Dm values obtaine
Arrows denote the peak positions of the miRNAs which reflect the sizes of
values for hypermethylation derived from this series (Additional file 8: Table
132 (asterisks). Reference peaks are indicated by arrowheads.the highest biomarker potential and became our main
focus in subsequent analyses.
Since the baseline levels of methylation may vary de-
pending on the locus and tissue type (Additional file 7:
Figure S3), thresholds for hypermethylation were deter-
mined for each miRNA based on Dm values in the
respective normal tissues (Methods, Additional file 8:
Table S5). Percentages of tumors with hypermethylation
(Additional file 7: Figure S3) were then used to compare
the different patient groups (Table 2). Among the three
miRNAs of our primary interest, miR-345 and 132 showed
hypermethylation in a significantly higher percentage of
MSI tumors (60% and 58%, respectively) than MSS tu-
mors (28% and 2%, respectively) from the Finnish sporadic
CRC series. Examination of Australian CRCs provided
independent additional proof by demonstrating that
hypermethylation of miR-345 and miR-132 significantly as-
sociated with MSI. Furthermore, hypermethylation percent-
ages of miR-132 distinguished Finnish sporadic MSI-CRCs
from Lynch-CRC (58% vs. 7%, P < 0.001). Hypermethyla-
tion of miR-129 and 345, respectively, was significantly
(P < 0.05) more common in Lynch-CRC (82% and 43%)
than that in Lynch-EC (44% and 8%), emphasizing tissue
specificity of methylation patterns. Finally, hypermethyla-
tion frequencies of several miRNAs differed between
Finnish and Australian CRCs, suggesting that methylation
patterns depend on geographic origin.strate a typical output from the custom-made MS-MLPA test.
d for each miRNA locus are given below the name of the miRNA.
the amplified fragments (Additional file 5: Table S3). Based on cutoff
S5), the tumor shows hypermethylation at miRNA loci 129-2, 663, and
Figure 3 Box-and-whisker plots of miRNA-specific distributions of methylation dosage ratios. The Dm values in paired tumor and normal
DNAs from each patient group are shown (please see the key for details). The horizontal line inside the box denotes the median, the upper and
lower edges are the 75th and 25th percentiles, and the bars indicate the highest and lowest Dm values. P values are based on t-test for paired
samples or Wilcoxon signed rank test. The miRNAs 129-2, 345, and 132 are shown in bold because their methylation pattern was considered the
most promising for further studies.
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more generalized methylator phenotype, the Dm values of
individual miRNAs were assessed against the proportion
of conventional tumor suppressor gene (TSGs) [11,16] or
CIMP markers methylated [17]. Methylation of miR-132
was significantly (P < 0.001 by Spearman analysis) corre-
lated with TSG methylation (Finland) or CIMP (Australia)
in sporadic MSI CRCs. Moreover, to prove that the ob-
served correlations did not depend on any particular def-
inition of a methylator phenotype, the Finnish tumors
were additionally examined with the same CIMP markers
used to classify Australian tumors [17], and the conclusion
remained unaltered (P = 0.006 for the correlation between
miR-132 methylation and CIMP). No significant correl-
ation was present in sporadic MSS CRCs or Lynch-CRCs.
The remaining miRNAs mostly did not show significant
correlations with a methylator phenotype.For analyses of clinical correlations, we evaluated pos-
sible associations of the Dm values for miR-129-2, 345,
and 132 with gender, age, grade, stage, and sidedness
among sporadic CRCs stratified by the MMR status. In
the combined series of CRCs from Finland and Australia,
the MSI CRCs revealed a significant association be-
tween miR-132 methylation and female gender (average
Dm was 0.28 in females, n = 47, vs. 0.14 in males, n = 31;
P = 0.003), increased age (across four age groups; P =
0.047), and proximal location in the bowel (average Dm
was 0.21 in proximal CRC, n = 61, vs. 0.11 in distal CRC,
n = 16; P = 0.000) when analyzed by the Kruskal-Wallis
test. MSS CRCs did not show significant differences in
these respects. For all three miRNAs, the average Dm
value for poorly differentiated (grade 3) CRCs exceeded
that of well-differentiated (grade 1) tumors regardless of
the MMR status, but the grade associations did not reach
Table 2 Comparison of tumors from different patient groups based on frequencies of hypermethylation at miRNA loci
Proportion of tumors with hypermethylationa
Tumor category 572 129-2 663 375-I 345 132 34a
MSI vs. MSS
Sporadic Finnish MSI-CRC (n = 40) vs.
sporadic Finnish MSS-CRC (n = 47)
13/40 vs. 13/47 37/40 vs. 34/47 28/40 vs. 28/47 0/40 vs. 1/47 24/40 vs. 13/47* 23/40 vs. 1/47*** 23/40 vs. 20/47
Sporadic Australian MSI-CRC (n = 38) vs.
sporadic Australian MSS-CRC (n = 52)
9/38 vs. 9/52 28/38 vs. 42/52 30/38 vs. 44/52 10/38 vs. 14/52 13/38 vs. 5/52* 15/38 vs. 6/52* 10/38 vs. 15/52
Sporadic vs. hereditary
Sporadic Finnish MSI-CRC (n = 40) vs.
Finnish Lynch-CRC (n = 28)
13/40 vs. 12/28 37/40 vs. 23/28 28/40 vs. 18/28 0/40 vs. 8/28** 24/40 vs. 12/28 23/40 vs. 2/28*** 23/40 vs. 13/28
Colorectal vs. endometrial
Finnish Lynch-CRC (n = 28) vs.
Finnish Lynch-EC (n = 36)
12/28 vs. 16/36 23/28 vs. 16/36* 18/28 vs. 22/36 8/28 vs. 5/36 12/28 vs. 3/36* 2/28 vs. 11/36 13/28 vs. 20/36
Finnish vs. Australian
Sporadic Finnish MSI-CRC (n = 40) vs.
sporadic Australian MSI-CRC (n = 52)
13/40 vs. 9/38 37/40 vs. 28/38 28/40 vs. 30/38 0/40 vs. 10/38** 24/40 vs. 13/38 23/40 vs. 15/38 23/40 vs. 10/38*
Sporadic Finnish MSS-CRC (n = 47) vs.
sporadic Australian MSS-CRC (n = 52)
13/47 vs. 9/52 34/47 vs. 42/52 28/47 vs. 44/52* 1/47 vs. 14/52** 13/47 vs. 5/52 1/47 vs. 6/52 20/47 vs. 15/52
aUsing cutoffs determined by methylation in the respective normal tissues (Additional file 8: Table S5). P values determined by Fisher’s exact test and adjusted for multiple testing are shown after each comparison,
(*P < 0.05; **P < 0.01; ***P < 0.001). All tumors were informative for all markers.
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correlate with stage.
Aberrant methylation of miRNA-associated CpG islands in
endometrial hyperplasia
To address the developmental stage at which epigenetic
alterations may arise, 29 normal endometrial tissues and
49 endometrial hyperplasias were screened for aberrant
methylation of the seven miRNAs of interest. Thresholds
for hypermethylation were determined on the basis of
Dm values in normal endometrial tissues (for sporadic
and Lynch cases separately, see Additional file 8: Table S5),
and the mean number of miRNAs with hypermethylation
(out of 7) per sample was calculated for the different types
of endometrial lesions (Figure 4A). In both sporadic and
Lynch series, normal endometrium and simple hyperplasia
(SH) clustered together to form a low-methylator group,
whereas complex hyperplasia without atypia (CH) and
complex hyperplasia with atypia (CAH) jointly constituted
a high-methylator group. When sporadic and Lynch cases
were combined, the low-methylator group (normal endo-
metrium + SH) had an average of 0.80 miRNAs with
hypermethylation out of 7 (11%), compared to 2.0 (28%)
in the high-methylator group (P = 0.00017 by t-test for in-
dependent samples).
Among the individual miRNAs, miR-129-2 was the
most discriminative between the different types of endo-
metrial lesions (Figure 4B) and displayed a progressively
increasing methylation from normal endometrium and
SH to CH and CAH (the mean Dm was 0.17 for normal
endometrium and SH vs. 0.28 for CH and CAH in the
combined sporadic and Lynch series, P < 0.0001 by t-test
for independent samples). Nine ECs were diagnosed in
the Lynch syndrome patients with hyperplasias, and the
average Dm was 0.25 in these ECs (data not shown).
Discussion
The available knowledge of cancer associations of miRNAs
is mainly derived from cell lines and unselected sporadic
forms of cancer. This study combined experiments on
cell lines and clinical specimens of sporadic and heredi-
tary CRCs and ECs to identify novel epigenetically regu-
lated miRNAs with translational relevance. Three miRNAs
(miR-129-2, miR-345, and miR-132) emerged as promising
targets for subgroup-specific methylation in CRC and EC
in our expressional screen and subsequent methylation
profiling of patient specimens (Figure 1).
To our knowledge, our study is the first to report miR-
132 as a methylation target in CRC and EC. Recent stud-
ies described hypermethylation of miR-132 in cancers of
the pancreas (hypermethylation frequency not given [18])
and prostate in 42% [19]. Downregulation of miR-132
has been observed in CRC tumors with distant metas-
tases [20]. In our investigation, hypermethylation of themiR-132-associated CpG island (in up to 58% of CRCs)
was associated with sporadic MSI CRC as opposed to
MSS CRC and distinguished sporadic MSI CRC from
Lynch-CRC (Table 2). Among sporadic MSI CRCs, miR-132
methylation was a particular property of tumors located
in the proximal colon (the average level of methylation in
distal MSI CRCs was similar to that in MSS CRCs irre-
spective of location). Recent reports suggest that the CIMP
status, and not MSI, may primarily determine the response
to adjuvant chemotherapy [21]. Given that hypermethyla-
tion of miR-132 was found to be part of a generalized TSG
methylator/CIMP phenotype, our findings imply that treat-
ment of MSI CRCs may need to be tailored according to
the proximal vs. distal location of the tumor.
MiR-345 was another miRNA showing differential
methylation between the various clinical groups exam-
ined (Table 2). While our study was in progress, Tang
et al. [22] reported hypermethylation of miR-345 in 87%
(27/31) of primary colorectal cancers by methylation-
specific PCR. When quantified by bisulfite genomic se-
quencing, the levels of methylation were relatively low
(16% for CRCs on the average), yet significantly higher
than in the paired non-cancerous mucosa (8.7% [22]). In
our MS-MLPA-based approach, a methylation dosage
ratio of 0.18 (corresponding to a methylation level of
18%) was used as the cut-off value for hypermethylation
of miR-345 in Finnish CRCs and a significant association
with sporadic MSI (as opposed to MSS) CRC emerged,
with a hypermethylation frequency of 60% (Table 2) and
average Dm 0.26 (Additional file 6: Table S4). Evaluation
of Australian CRCs confirmed the observed association
of miR-345 with MSI (Table 2).
Our findings regarding miR-129-2 were important in
two respects. First, miR-129-2 displayed the highest fre-
quencies of hypermethylation among all seven miRNAs
analyzed (93% for sporadic Finnish CRC, Table 2). Second,
in a series of endometrial hyperplasias, hypermethylation
of miR-129-2 progressively increased along with the in-
creasing severity of the lesion (Figure 4B). Published
studies indicate that hypermethylation of the miR-129-2-
associated CpG island is common in human cancers, oc-
curring in 91% of CRC [23], 69% of gastric cancers [24],
68% of EC [25], and 58% of hepatocellular carcinomas
[26]. Moreover, correlation of hypermethylated miR-129-2
with MSI, MLH1 methylation, and poor survival in EC has
been reported [25]. Earlier studies have not examined
the occurrence of miR-129-2 hypermethylation in steps
preceding malignant transformation. We showed that
miR-129-2 methylation stratified endometrial specimens
into two groups, one with low methylation (normal endo-
metrium and SH) and another one with a significantly
higher methylation (CH and CAH). It remains controver-
sial which lesions should be considered as precursors to
EC, and the miRNA data, together with our previous
Figure 4 Average percentages of hypermethylated miRNAs and box-and-whisker plots. (A) Average percentages of hypermethylated
miRNAs out of 7 per endometrial sample. The set of miRNAs include miR-572, 129-2, 663, 375-I, 345, 132, and 34a. Specimens of normal endometrium
(N) and endometrial hyperplasias of increasing severity (SH, CH, and CAH) are displayed. Sporadic and Lynch syndrome-associated cases are shown
separately (see the ‘Methods’ section for sample sizes). (B) Box-and-whisker plots for the distribution of Dm values for 129-2 in normal endometrium
and endometrial hyperplasias. Sporadic and Lynch syndrome-associated cases were combined since they revealed similar distributions when
analyzed individually.
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ance of complex hyperplasia, with or without atypia, as a
precursor lesion of EC.
Existing literature is scarce regarding the role of ethnic
or geographic origin as a modifier of epigenetic patterns
in cancer. While the causes for the significant differences
in hypermethylation frequencies between sporadic CRCs
from Finland and Australia (Table 2) are unknown, dif-
ferent environments [28] or population-specific featuresof the genetic constitution [29] could play a role. We re-
cently described distinct epigenetic signatures of conven-
tional TSGs for CRCs from Finland and Egypt, suggesting
the possible effect of environmental exposures on colorec-
tal carcinogenesis [30]. The selective targeting hypothesis
for CIMP [31] postulates that certain regions of the gen-
ome may have intrinsic features that attract DNA methyl-
transferases: for example, a common polymorphism in
the MLH1 promoter region (−93G > A) was shown to
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MSS-CRCs did not show this association [32]. It is pos-
sible that the promoter regions of the miRNAs we studied
harbor genetic variation between populations. However,
the genetic homogeneity of the Finnish series (exclusively
of Finnish origin) but considerable heterogeneity of the
Australian series (of diverse ethnic origins) may make a
genetic explanation less likely compared to the impact of
different environments.
Multiple techniques are available for quantitative and
qualitative analysis of methylation, each with advantages
and disadvantages [33,34]. MethyLight, pyrosequencing,
COBRA, and MS-MLPA represent methods suitable for
quantitative methylation analysis for biomarker purposes.
No need of bisulfite conversion distinguishes MS-MLPA
from the other methods mentioned above. This is a clear
advantage with respect to FFPE samples in particular
which may result in non-reproducible bisulfite conver-
sions and hence varying methylation levels [35]. The sim-
ultaneous analysis of multiple genes in a single assay saves
template DNA and is another advantage of MS-MLPA
over the remaining techniques. A drawback is that MS-
MLPA only assesses one or two CpG sites (recognized
by HhaI) for any given gene, whereas pyrosequencing
allows quantitative analysis of methylation at multiple
CpG sites [36-39]. This disadvantage of MS-MLPA
can be alleviated by choosing CpG sites with methyla-
tion status reflecting that of the surrounding CpGs
(this study, [40]); by doing so, methylation levels by
MS-MLPA and pyrosequencing have turned out to be
concordant [40]. In comparison with bisulfite sequen-
cing, MS-MLPA and pyrosequencing share the advan-
tage of not requiring any cloning step for accurate
quantification of methylation. A good agreement be-
tween Dm values from MS-MLPA and proportions of
methylated DNA by cloning is evident from previous
studies [16,41] and this investigation (Additional file 9:
Figure S4). Finally, MS-MLPA and pyrosequencing are
both sensitive, being able to detect low percentages of
methylated DNA (10% to 15% or even below; [36,42]) and
specific when evaluated against results obtained by inde-
pendent methods (this study, [36,39]).
CpG island methylation and expression of mature
miRNAs, including miR-129-2 [26], miR-345 [22], and
miR-132 [18] are inversely correlated suggesting that
methylation is functionally significant. Inverse trends for
these miRNAs were also evident in the colorectal and
endometrial cancer cell lines and respective normal tis-
sues we investigated, although the trends failed to reach
statistical significance. Functional studies have established
that miR-129-2 [25], miR-345 [22], and miR-132 [19]
are all tumor-suppressive. Verified targets for miR-129-2
(SOX4 and CAMTA1, [25]; CDK6, [43]; and EIF2C3/
AGO3, [44]), miR-345 (BAG3, [22]), and miR-132 (HB-EGF and TALIN2, [19]) suggest that silencing of these
miRNAs can have important tumorigenic consequences.
Altered expression of miRNAs [45-48] is known to be
involved in the multistage colorectal [10] and endomet-
rial tumorigenesis [49], and aberrant DNA methylation
which may underlie expression changes can be utilized
in preventive and therapeutic interventions. The miR-
NAome provides a tool for molecular subclassification
of cancers for the purposes of diagnosis, prognostic assess-
ment, and treatment. Sporadic MSS-CRCs behave differ-
ently compared to their MSI counterparts, and the latter
differ from CRCs arising in LS; the differential behavior
can at least in part be attributed to epigenetic alterations
and their associations with other molecular markers [50].
Differentiation between sporadic MSI, sporadic MSS,
and LS-associated CRCs may be possible on the basis
of miRNA expression [51-53] and/or methylation pat-
terns ([16] and this study). In our series, MMR-deficient
tumors (from LS and sporadic cases) were enriched, and
therefore, all clinicopathological correlations we report
need to be independently evaluated in large unselected
series for confirmation.
Conclusions
Our investigation provides new insights into colorectal and
endometrial tumorigenesis since it (i) links epigenetic in-
activation of miR-132 and miR-345 to specific subtypes of
colorectal carcinoma, especially with respect to MSI status,
(ii) pinpoints miR-129-2 as an important player in the early
steps of endometrial tumorigenesis, (iii) shows differential
involvement of miRNAs in hereditary vs. sporadic cancers,
and (iv) provides suggestive evidence to support the role of
geographic and/or ethnic origin as a modifier of patterns
of miRNA methylation in tumors. The observed miRNA
alterations may warrant closer evaluation for biomarker
potential for clinical applications.
Methods
Patients and samples
This investigation included 205 CRCs and 36 endomet-
rial carcinomas (EC) and paired normal tissues (Table 1).
The sporadic CRCs represented consecutive series from
Finland [11,54] and Australia [55], with MMR status
used as a selection criterion to include MMR-proficient
and MMR-deficient tumors in roughly equal propor-
tions. Tumors with unstable BAT25 or BAT26 were con-
sidered to have MSI, whereas those with normal BAT25
and BAT26 were microsatellite-stable (MSS). BAT25 and
BAT26 are mononucleotide repeat markers from the five-
marker Bethesda panel [56] and have been shown to be
sensitive and specific indicators of the MSI-high phenotype
[57,58]. Immunohistochemical (IHC) analysis of MMR
protein expression for Finnish tumors was as described
[11] and for Australian tumors conducted by standard
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MSH2 clone 25D12 (Leica 1:250), MSH6 clone BC/44
(Biocare 1:100), and PMS2 clone A16-4 (BD Pharmingen
1:500) as primary antibodies. In addition to the series de-
scribed in Table 1, an endometrial series [27] including 29
normal endometrial tissues (14 sporadic, 15 Lynch syn-
drome), 12 simple hyperplasias (10 sporadic, 2 Lynch
syndrome), 13 complex hyperplasias without atypia (8
sporadic, 5 Lynch syndrome), and 24 complex hyper-
plasias with atypia (10 sporadic and 14 Lynch syndrome)
was investigated. Following histological evaluation, tumor
and hyperplasia samples were procured by appropriate
methods to ensure high percentages of tumor and hyper-
plasia cells [11,27,50,59]. DNA was subsequently extracted
from selected regions of FFPE and fresh frozen tumors
from Finland using the protocol by Isola et al. [60]
and from Australian FFPE samples by the Puregene DNA
Isolation Kit (Centra, Minneapolis, MN, USA).
The study of Finnish cases was approved by the insti-
tutional review board of the Helsinki University Central
Hospital (Dnro 466/E6/01) and the National Authority for
Medicolegal Affairs (Dnro 1272/04/044/07). For Australian
cases, Human Ethics approval was granted by the Ethics
Review Committees of Sydney South West Area Health
Service (Royal Prince Alfred and Liverpool Hospitals) by
protocol numbers X08-0224 and SSA/09/LPOOL/23.
Drug treatment of cell lines
Five colorectal and two endometrial cancer lines (Additional
file 1: Table S1) from the American Type Culture Collection
(Rockville, MD, USA) were cultured according to the sup-
plier’s protocol. Demethylation studies were performed as
described [61]. Cells were treated with 5 μM 5-aza-2′
deoxycytidine (Sigma, A3656; Sigma-Aldrich, St. Louis,
MO, USA) for 96 h and with 300 nM trichostatin (Sigma,
T1952) for 18 h. All treatments were performed in dupli-
cates. DNA was isolated using standard protocols and total
RNA extracted with miRNeasy mini kit (Qiagen, Valencia,
CA, USA). The efficiency of the drug treatments was
confirmed by expressional (TaqMan®) and methylation
(SALSA MS-MLPA ME001-C1 Tumor suppressor-1
kit, MRC-Holland, Amsterdam, the Netherlands) analyses
of selected tumor suppressor genes in all cell lines, as well
as by IHC analysis of MLH1 in RKO.
Genome-wide miRNA profiling
Agilent’s human miRNA microarrays (8 × 15 K from
Agilent Technologies, G4470B; Agilent Technologies,
Inc., Santa Clara, CA, USA) containing 723 human and 76
human viral miRNAs sourced from the Sanger miRBase,
v. 10.1 were used. Signal intensities of fluorescence were
calculated by Agilent’s Feature Extraction software ver-
sion 10.7.3.1. Microarrays were investigated in duplicates
for each cell line. GeneSpring GX software, version 11.0.2(Agilent Technologies) was used for miRNA data analysis.
Data was normalized by quantile normalization. Statisti-
cally significant differentially expressed miRNA were iden-
tified by t-test unpaired combined with the Benjamini and
Hochberg correction for multiple testing and using filters
based on P-value cutoff 0.05 and fold change cutoff ±2.00.
The miRNA expression profiling data have been submit-
ted to GEO (accession number GSE55930).
CpG island definition and analysis by bisulfite sequencing
The regions of regularly up to 3 kb upstream of the mature
miRNAs [62] were screened for CpG islands and the
miRNA gene promoter regions defined by the EMBOSS
CpGplot (http://www.ebi.ac.uk/Tools/seqstats/emboss_
cpgplot) and CpG island searcher (http://ccat.hcs.usc.
edu/cpgislands2) programs.
Methylation statuses of the CpG sites in a miRNA-
associated CpG island were determined by bisulfite se-
quencing. In brief, DNAs from cancer cell lines (Additional
file 1: Table S1) and normal blood or tissue donors (healthy
female and male donor DNA from Promega, Madison, WI,
USA, CatG152A and CatG147A; normal colon DNA from
Amsbio, Abingdon, UK, LotA805046, and normal uterus
DNA from Amsbio, Abingdon, UK, LotB403076) were
bisulfite-converted using EZ DNA Methylation-Direct™
Kit (Catalog Number D5021, Zymo Research Corporation,
Irvine, CA, USA). Bisulfite-modified DNA was ampli-
fied by methylation-unbiased primers (Additional file 4:
Table S2) designed with the assistance of MethPrimer-
program (http://www.urogene.org/cgi-bin/methprimer/
methprimer.cgi) or manually.
Amplification products were sequenced either directly
or after cloning. For the latter, amplification products
were cloned into a pCR2.1 TOPO vector using the TOPO
TA Cloning System (Invitrogen, Carlsbad, CA, USA), and
DNAs extracted from the resulting white colonies were
sequenced.
MS-MLPA for methylation studies of miRNAs
CpG dinucleotides that were part of the restriction site
for the methylation-sensitive enzyme HhaI (GCGC) and
with methylation status representative of a larger region
as determined by bisulfite sequencing were chosen for
the design of probes for custom-made MS-MLPA. In
MS-MLPA, a signal peak is generated if the sample DNA
is methylated, which protects the DNA probe hybrids
against HhaI digestion and the ligated probes can be
exponentially amplified by PCR. MS-MLPA probes spe-
cific for the miRNAs of interest were designed according
to the protocol of MRC-Holland (www.MRC-Holland.
com) (Additional file 3: Figure S2 and Additional file 5:
Table S3).
All selected miRNAs were interrogated by one MS-MLPA
probe except for miR-375 with two probes. The synthetic
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Reference-2 kit (MRC-Holland, Amsterdam, the Netherlands)
for control probes lacking Hha1 sites to make a complete
MS-MLPA assay. Amplification products were visualized
by fragment analysis and methylation dosage ratios (Dm)
calculated as described [12].
Custom MS-MLPA assays were optimized and vali-
dated by a previously outlined protocol [16,41]. In brief,
technical thresholds for a reliable detection of methyla-
tion were determined by evaluating MS-MLPA results
against bisulfite sequencing. Dm = 0.15 (corresponding
to 15% methylated DNA) turned out to be the technical
threshold for the present miRNAs based on comparative
analyses showing that Dm < 0.15 by MS-MLPA corre-
sponded to unmethylated sequence (T/T) and Dm ≥ 0.15
to partially (C/T) or completely (C/C) methylated sequence
by direct bisulfite sequencing. More accurate quantification
of methylation to validate the results was obtained by se-
quencing of cloned bisulfite-converted PCR-amplified frag-
ments as described [16,41]. All seven miRNAs of interest
were validated by direct bisulfite sequencing and miR-129-2,
miR-345, and miR-132 additionally by cloning. To illustrate
the validation procedure, miR-129-2 is shown as an example
in Additional file 9: Figure S4.
In this paper, the term hypermethylation is used to indi-
cate higher methylation in tumor DNA relative to normal
DNA, with miRNA-specific numerical thresholds defined
as the average Dm in normal DNA of the same tissue type
(colorectal mucosa or normal endometrium) plus one
standard deviation (if the calculation resulted in a value
below the technical threshold, the technical threshold was
used instead) (Additional file 8: Table S5).
TSG methylator phenotype and CIMP
The TSG methylator phenotype for Finnish tumors
was established by the SALSA MS-MLPA ME001-C1
Tumor suppressor-1 kit (MRC-Holland, Amsterdam, The
Netherlands) as described [11]. Sporadic MSI CRCs
were additionally studied with the SALSA MS-MLPA
ME042-B2 CIMP kit (MRC-Holland, Amsterdam, The
Netherlands) for verification. The CIMP phenotype for
Australian tumors was based on the CACNA1G, IGF2,
NEURO1G, RUNX3, and SOCS1 markers [63] and was
determined by Methylight analysis of bisulfite-converted
DNA (EpiTect Bisulfite Kit, Qiagen, Valencia, CA, USA)
as described [17].
Statistical analyses
Statistical analyses were performed using SPSS Statistics
Software (IBM SPSS, Inc., Chicago, IL, USA). Statistical
significance for the differences between distributions
was evaluated as follows. Depending on whether or
not the data were normally distributed (as evaluated by
Shapiro-Wilk test), a parametric or non-parametric test,respectively, was chosen. For pairwise analysis of corre-
lated samples (intra-group comparisons), t-test (parametric)
or Wilcoxon signed rank test (nonparametric) was used.
To evaluate the significance of difference between the
means of two independent groups (inter-group compari-
sons), t-test (parametric) or Mann-Whitney U test (non-
parametric) was applied. The percentages of tumors with
hypermethylation (Table 2 below) were compared by
Fisher Exact Probability Test from VassarStats Web site
(www.vassarstats.net/tab2x2.html). For the comparison of
multiple (≥3) independent groups, one-way ANOVA and
Kruskal-Wallis test were used for parametric and non-
parametric analyses, respectively, followed by appropriate
post-hoc tests. For correlations, the Pearson product-
moment correlation coefficient (r) for linear correlation
was determined for parametric data and the Spearman
rank correlation coefficient (rho) for non-parametric data.
P values <0.05 (two-tailed) were considered significant.
Additional files
Additional file 1: Table S1. Characteristics of cell lines studied.
Additional file 2: Figure S1. Venn diagram showing the number of
miRNAs (among all significantly upregulated 109) which were specific to
a given group or alternatively, shared between different groups of cancer
cell lines. MMR-D EC includes HEC59 and AN3CA, MMR-P CRC includes
T84 and SW480, and MMR-D CRC includes HCT15, HCT116, and RKO. The
miRNAs associated with CpG islands are underlined, and those selected
for this study are in bold.
Additional file 3: Figure S2. Schematic figure of the CpG island-containing
region associated with each miRNA. The locations of the MS-MLPA probes
(gray boxes) and the primers for bisulfite sequencing (BS, black arrowheads)
are given. The location of the mature miRNA is shown by a thin arrow
which indicates transcriptional direction.
Additional file 4: Table S2. Sequences for bisulphite sequencing primers.
Additional file 5: Table S3. Sequences for MS-MLPA probes.
Additional file 6: Table S4. Average methylation dosage ratios and
standard deviations for paired tumor and normal tissues shown in
Figure 3.
Additional file 7: Figure S3. Percentages of tumors with
hypermethylation relative to the respective normal tissues at the seven
individual miRNA loci. The exact percentage is given above each bar.
Please see Additional file 8: Table S5 for cut-off values for hypermethylation
and Table 2 for statistical analysis of group-specific comparisons.
Additional file 8: Table S5. Normal tissue-based threshold values for
the detection of hypermethylation at miRNA loci in tumor tissues.
Additional file 9: Figure S4. The design and validation of MS-MLPA
assays showing miR-129-2 as an example. Bisulphite-converted DNA from
cancer cell lines and normal tissues was first sequenced to select a
representative region for MS-MLPA probe design (see Methods). Results
from direct bisulphite sequencing (without cloning) are depicted on the left,
with methylation status of each CpG site coded as T/T (unmethylated),
C/T (partially methylated), or C/C (methylated). Quantification of DNA
methylation (proportion of methylated DNA) by two parallel methods,
MS-MLPA and sequencing of cloned bisulphite-converted PCR-amplified
fragments, is shown on the right. Dm values by MS-MLPA were concordant
with results from the cloning analysis.
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